Halozyme added James Daly to its board, with pay that includes cash, stock awards, and options. The filing reports no special deal or business change, so it does not alter the company's outlook.
The disclosed pay includes cash and stock awards, so the appointment carries a cost. The filing reports no special deal or related-person transaction, and no change to Halozyme's business.
Follow Halozyme Therapeutics, Inc. (HALO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HALO